A retrospective analysis presented at the American Society of Clinical Oncology 2025 Annual Meeting suggests that higher tumor mutational burden (TMB) may be linked to longer progression-free survival in...
The latest OVATION-2 trial update, presented at the American Society of Clinical Oncology 2025 annual meeting, shows that adding intraperitoneal IMNN-001 to standard neoadjuvant chemotherapy improved both...
A phase II trial evaluating pembrolizumab plus lenvatinib in clear cell ovarian carcinoma shows promising response rates and 6-month progression-free survival.
A retrospective analysis from Memorial Sloan Kettering links higher patient-reported pain to increased emergency department utilization among individuals newly diagnosed with ovarian cancer. This study was...
